Choong-wae to conduct Phase 3 trial over new biological therapy, Actemra

Published: 2009-06-19 06:58:00

Updated: 2009-06-19 06:58:00

Choong-wae Pharm said on June 17 that the Korea Food and Drug Administration has approved Phase 3 study of Actemra (tocilizumab), to treat patients with rheumatoid arthritis (RA).

The company entered into an exclusive license agreement with Chugai to develop, market, sell and distribute Actemr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK